Jeffrey Salazar
Bariatric surgery is an increasingly recognized treatment for obesity in patients with chronic kidney disease (CKD). It is associated with a lower 5-year risk of mortality and has been shown to improve renal function in patients with CKD. However, there are also renal risks associated with the surgery, including acute kidney injury, nephrolithiasis, and oxalate nephropathy. The impact of bariatric surgery on the renal functions of patients with CKD is still being studied, and the specific dietary changes that may be required post-surgery are not yet fully understood.
Explore related products
$8.43 $18.99
$15.8 $16.99
$9.69 $17.99
What You'll Learn
- Bariatric surgery is a safe and effective treatment for obesity in patients with chronic kidney disease (CKD)
- Sleeve gastrectomy (SG) is the most commonly performed weight-loss procedure for CKD patients
- SG has a low post-procedure mortality rate, but the risk of death is higher for patients with CKD stage 5D
- Bariatric surgery can improve renal function in CKD patients
- Bariatric surgery can reduce the risk of heart attacks and strokes in people with diabetes and severe obesity
Bariatric surgery is a safe and effective treatment for obesity in patients with chronic kidney disease (CKD)
Bariatric surgery is increasingly being recognised as a safe and effective treatment for obesity in patients with chronic kidney disease (CKD). CKD is a condition characterised by a gradual loss of kidney function over time, and it affects 15% of adults worldwide, often leading to reduced life expectancy. The prevalence of severe obesity in the CKD population is also on the rise, with over one-fifth of CKD patients in the United States having a body mass index of ≥35 kg/m2.
Bariatric surgery has been shown to be an effective method for achieving sustained weight loss in patients with CKD. It can also improve blood pressure, reduce hyperglycaemia, and even induce diabetes remission. One study found that bariatric surgery was associated with a 79% lower 5-year risk of mortality in adults with CKD and obesity compared to a similar group that did not undergo the procedure. Another study found that the 5-year mortality rate for patients with CKD and severe obesity who did not have the surgery was 14.6%, while the rate for those who did have the surgery was significantly lower at 4.9%.
Among the available surgical methods, sleeve gastrectomy (SG) is the most commonly performed weight loss procedure for patients with CKD. SG has been shown to improve renal function as early as 12 months after surgery. However, it is important to note that the risk of death is 47% higher among patients with CKD stage 5D in the first year after SG compared to well-matched non-SG controls. There are also other renal risks associated with bariatric surgery, including acute kidney injury, nephrolithiasis, and, in rare cases, oxalate nephropathy.
Overall, while bariatric surgery is a promising treatment option for obesity in patients with CKD, more research is needed to fully characterise its effects on renal function.
Fish-Centric Diets: Exploring Varied Nutritional Options
You may want to see also
Explore related products
Sleeve gastrectomy (SG) is the most commonly performed weight-loss procedure for CKD patients
Bariatric surgery is a safe and effective treatment for obesity in patients with chronic kidney disease (CKD). It is also effective in improving blood pressure, reducing hyperglycemia, and even inducing diabetes remission.
SG is often performed to facilitate kidney transplantation (KT). However, many KT candidates treated with SG remain on the transplant waiting list for extended periods, and some never receive a transplant. Therefore, appropriate candidates for SG must be carefully selected, and post-SG management should address the unique needs of this population.
SG can improve kidney function independently of weight loss. It has been shown to improve glomerular function and renal blood flow in patients with severe obesity and baseline CKD stage ≥2. SG is also advantageous due to its lack of association with kidney stones or oxalate nephropathy, which are risks associated with other types of bariatric surgery.
Foods to Eat and Avoid for Less Gas
You may want to see also
Explore related products
SG has a low post-procedure mortality rate, but the risk of death is higher for patients with CKD stage 5D
Sleeve gastrectomy (SG) is a common weight-loss procedure for patients with chronic kidney disease (CKD). It is considered a safe and effective treatment for obesity in patients with CKD, including stages 4, 5, and 5D (on dialysis). SG has a low overall post-procedure mortality rate, but it is important to note that patients with CKD stage 5D face a significantly higher risk of death in the first year after the procedure compared to non-SG patients.
CKD is a progressive condition characterised by abnormalities in kidney function and structure. It is associated with an increased risk of cardiovascular disease, which is the leading cause of death in this patient population. The risk of sudden cardiac death is particularly high in patients with CKD stage 5D, with a rate of 59 deaths per 1,000 patient-years, compared to 1 death per 1,000 patient-years in the general population.
The high mortality risk in CKD stage 5D patients undergoing SG may be attributed to several factors. Firstly, these patients often require kidney transplantation (KT), and the long waiting times for a transplant can impact their overall health. Secondly, rapid weight loss after SG can lead to muscle and bone catabolism, which may contribute to adverse health outcomes. Additionally, patients with CKD stage 5D are at an increased risk of hypoglycaemia, which can be asymptomatic and challenging to manage, especially in the post-SG period.
To improve outcomes for CKD stage 5D patients undergoing SG, multidisciplinary post-operative care is essential. This includes addressing the unique needs of this population, such as sustaining the metabolic benefits of surgery while minimising potential side effects. Optimising overall health before and after SG can help reduce the high mortality risk associated with CKD stage 5D.
While SG has shown promising results in treating obesity and improving kidney function in CKD patients, the increased risk of death in CKD stage 5D patients underscores the importance of careful patient selection and comprehensive post-operative management. Further research is also needed to fully understand the impact of SG on this high-risk population.
Blood Type Diet: Science or Fiction?
You may want to see also
Explore related products
Bariatric surgery can improve renal function in CKD patients
Bariatric surgery is an effective treatment for obesity, hypertension, and type 2 diabetes mellitus. It has been shown to improve renal function in patients with chronic kidney disease (CKD).
CKD is a condition characterized by a gradual loss of kidney function over time, and it affects 15% of adults worldwide. The risk factors for CKD include obesity, cardiac disease, family history of CKD, inherited kidney disorders, previous renal injuries, older age, and a high BMI. Obesity is a significant and independent risk factor for the onset of albuminuria and an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2.
Bariatric surgery has been found to reduce the incidence and slow the progression of CKD. In a study of patients with stage 3 CKD who underwent bariatric surgery, renal function improved over the first 6 months, with a decrease in proteinuria and a stable GFR. Another study found that bariatric surgery was associated with a 79% lower 5-year risk of mortality in patients with CKD and obesity compared to those who did not undergo the procedure.
The benefits of bariatric surgery for patients with CKD and obesity include a reduction in body weight, which can induce positive changes in renal manifestations. Additionally, bariatric surgery has been shown to improve key parameters of kidney injury at the functional, structural, and ultrastructural levels. It also affects a program of transcriptomic change in the kidney that is consistent with injury resolution.
While bariatric surgery has been shown to improve renal function in patients with CKD, it is important to note that the surgery may carry a slightly higher risk for patients with CKD. The risk of death is 47% higher among patients with CKD stage 5D in the first year after surgery compared to non-surgical controls. However, the benefits of the surgery, such as improved renal function and reduced mortality, appear to outweigh the risks for carefully selected patients.
Who Portrayed Sven in Santa Clarita Diet?
You may want to see also
Explore related products
Bariatric surgery can reduce the risk of heart attacks and strokes in people with diabetes and severe obesity
Obesity is a risk factor for the progression of chronic kidney disease (CKD). In fact, severely obese patients with an accompanying diagnosis of diabetes carry the highest risk for CKD. Bariatric surgery is an effective therapy for obesity, hypertension, and type 2 diabetes mellitus that is refractory to maximal medical therapy. Results of long-term cohort studies and emerging evidence from randomized clinical trials have revealed that, in addition to its beneficial effects on weight reduction, blood pressure, and metabolic control, bariatric surgery might reduce the incidence and long-term progression of CKD.
Bariatric surgery can also reduce the risk of heart attacks and strokes in people with diabetes and severe obesity. A study tracked about 20,000 severely obese patients with Type 2 diabetes, finding that those who had weight-loss surgery were 40% less likely to develop a heart attack or stroke in the five years following surgery compared to those who received regular care. The study also found that for every 1,000 patients who had surgery, there were roughly 20 heart attacks or strokes compared to 40 such events per 1,000 who received regular care.
Another study found that obese patients who underwent bariatric surgery were 40% less likely to have a heart attack or stroke within five years, 33% less likely to develop heart disease, and 67% less likely to die from any cause. However, the success of the surgery was determined by how much weight the patients kept off afterward. If they regained at least 20% of the weight lost, they were one-third likely to develop diabetes and two-thirds likely to have high cholesterol.
Bariatric surgery can affect hormones, gut bacteria, and other substances that influence how the body handles insulin and blood sugar. While bariatric surgery is thought to be safe, it carries a small chance of life-threatening complications, and some people may need to have the surgery repeated. The cost of bariatric surgery typically ranges from $20,000 to $25,000, although insurance coverage is increasingly available.
Mountain Dew Mystery: Who Owns Diet Mountain Dew?
You may want to see also
Frequently asked questions
Bariatric surgery is a weight-loss procedure that is recognised as a safe and effective treatment for obesity in patients with chronic kidney disease (CKD).
Bariatric surgery is associated with a lower 5-year risk of mortality in patients with CKD and obesity. It also helps improve renal function, with a decrease in proteinuria and a stable glomerular filtration rate (GFR). However, there are also renal risks in bariatric surgery, including acute kidney injury, nephrolithiasis, and oxalate nephropathy.
The risk of death is 47% higher among patients with CKD stage 5D in the first year after surgery compared to non-CKD patients. There is also a risk of developing hypoglycaemia after surgery, which is higher in patients with renal failure.
Bariatric surgery patients are required to undergo a medical weight-loss program involving monthly physician-supervised visits with a dietitian. A dietitian will be able to advise on any necessary dietary changes.
